Breaking News, Promotions & Moves

Tanvex BioPharma Names New CEO

Stephen Lam succeeds Henry Chen, effective September 5, 2024.

Author Image

By: Charlie Sternberg

Associate Editor

Tanvex BioPharma Inc., the biosimilar-focused biopharmaceutical company and CDMO, has appointed Stephen Lam as its Chief Executive Officer, effective September 5, 2024.   Lam succeeds Henry Chen, who will remain the Chairman until the closing of Tanvex’s strategic alliance with Bora Pharmaceuticals Co., Ltd. ​ As a part of the new leadership initiated by Bora, Lam will be responsible for ensuring a successful integration, driving the Company’s strategic initiatives as well as overseeing Tanv...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters